2592
This phase 3, randomized, double-blind 1-yr study assessed the effects of combined RLX and ALN in 331 postmenopausal women with osteoporosis (femoral neck BMD T-score, less than -2).
 331 postmenopausal women with osteoporosis (femoral neck BMD T-score, less than -2): Subject; 331: Subject.Population; women: Subject.Gender; postmenopausal: Subject.Age; combined RLX and ALN: Treatment; osteoporosis: Treatment.Disorder; RLX: Treatment.Drug; ALN: Treatment.Drug; RLX: Combination.Drug; ALN: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: potential therapeutic event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Treatment.Time_elapsed, Subject.Disorder, Subject.Race, Treatment.Route, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 331 postmenopausal women with osteoporosis (femoral neck BMD T-score, less than -2): Subject; 331: Subject.Population; women: Subject.Gender; postmenopausal: Subject.Age; combined RLX and ALN: Treatment; osteoporosis: Treatment.Disorder; RLX: Treatment.Drug; ALN: Treatment.Drug; RLX: Combination.Drug; ALN: Combination.Drug